Similar Articles
1311 Percutaneous radiofrequency ablation for early hepatocellular carcinoma: Risk factors for survival
1312 Transjugular intrahepatic portosystemic shunt with covered stents for hepatocellular carcinoma with portal vein tumor thrombosis
1313 Novel hepatocellular carcinoma molecules with prognostic and therapeutic potentials
1314 Management of hepatocellular carcinoma: The role of contrast-enhanced ultrasound
1315 Predictors of survival in patients with established cirrhosis and hepatocellular carcinoma treated with sorafenib
1316 Bortezomib effect on E2F and cyclin family members in human hepatocellular carcinoma cell lines
1317 Epigenetics in hepatocellular carcinoma: An update and future therapy perspectives
1318 Targeting of circulating hepatocellular carcinoma cells to prevent postoperative recurrence and metastasis
1319 ALK gene copy number gain and its clinical significance in hepatocellular carcinoma
1320 Epirubicin, Cisplatin, 5-FU combination chemotherapy in sorafenib-refractory metastatic hepatocellular carcinoma
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA